

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Syvazul BTV suspension for injection for sheep and cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances*:

Inactivated bluetongue virus (BTV)	RP** ≥ 1
------------------------------------	---------------

* Maximum of two different inactivated bluetongue virus serotypes:

Inactivated bluetongue virus, serotype 1 (BTV-1), strain ALG2006/01 E1
Inactivated bluetongue virus, serotype 4 (BTV-4), strain BTV-4/SPA-1/2004
Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01

** Relative potency measured by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species.

The number and type(s) of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label.

Adjuvants:

Aluminium hydroxide (Al ³⁺)	2.08 mg
Semi-purified saponin from <i>Quillaja saponaria</i>	0.2 mg

Excipient:

Thiomersal	0.1 mg
------------	--------

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Suspension for injection.

Pinkish-white suspension easily homogenised by shaking.

4. CLINICAL PARTICULARS

4.1 Target species

Sheep and cattle.

4.2 Indications for use, specifying the target species

Sheep:

For active immunisation of sheep to prevent viraemia* and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes).

*Below the level of detection by the validated RT-PCR method at 1.32 log₁₀ TCID₅₀/ml

Onset of immunity: 39 days after completion of the primary vaccination scheme.

Duration of immunity: one year after completion of the primary vaccination scheme.

Cattle:

For active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes).

*Below the level of detection by the validated RT-PCR method at $1.32 \log_{10}$ TCID₅₀/ml

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: one year after completion of the primary vaccination scheme.

4.3 Contraindications

None.

4.4 Special warnings for each target species

Vaccinate healthy animals only.

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.

No information is available on the use of the vaccine in sheep with maternally-derived antibodies.

No information is available on the use of the vaccine containing BTV4 serotype in cattle with maternally-derived antibodies.

4.5 Special precautions for use

Special precautions for use in animals

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

People with known hypersensitivity to aluminium hydroxide, thiomersal or saponins should avoid contact with the veterinary medicinal product.

4.6 Adverse reactions (frequency and seriousness)

The development of local reactions is very common at the site of injection after vaccination.

Erythema associated with mild to moderate oedema is very common from 1 to 6 days after the administration.

A painless nodule that may reach up to 3.8 cm diameter in sheep and 7 cm diameter in cattle develops very commonly after 2 to 6 days and diminishes progressively over time.

An abscess may appear on rare occasions.

Most local reactions disappear or become residual (≤ 1 cm) before 70 days in sheep and 30 days in cattle, although residual nodules can persist after that time.

A transient increase in rectal temperature, not exceeding 2.3 °C, during the 48 hours following vaccination, is very common.

The following might be observed on rare occasions in sheep and on very rare occasions in cattle:

- Reproductive system disorders: abortion, perinatal mortality or premature parturition
- Systemic disorders: apathy, recumbency, fever, anorexia or lethargy.

The following might be observed on very rare occasions in sheep and cattle:

- Reduction in milk production
- Neurological disorders: paralysis, ataxia, blindness or incoordination
- Respiratory tract disorders: pulmonary congestion, dyspnoea
- Digestive tract disorders: rumen atony or bloating
- Hypersensitivity reactions: with hypersalivation
- Death.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Pregnancy:

Can be used during pregnancy.

Lactation:

Can be used during lactation.

Fertility:

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or National Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Shake well before use.

Sheep:

Subcutaneous use.

Administer subcutaneously to sheep from 3 months of age, according to the following scheme:

- Primary vaccination: administer a single 2 ml dose.
- Revaccination: administer one dose of 2 ml after 12 months.

Cattle:

Intramuscular use.

Administer intramuscularly to cattle from 2 months of age in naïve animals or from 3 months of age in calves born to immune cattle, according to the following scheme:

- Primary vaccination: administer two doses of 4 ml 3 weeks apart.
- Revaccination: administer one dose of 4 ml after 12 months.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

After administration of a double dose, no other adverse reactions different to those mentioned in section 4.6 were observed.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Inactivated bluetongue virus vaccines for sheep.
ATCvet code: QI04AA02.

To stimulate active immunity of sheep and cattle against bluetongue virus serotypes 1, 4 and/ or 8 related to those contained in the vaccine (combination of maximum 2 serotypes).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Aluminium hydroxide
Semi-purified saponin from *Quillaja saponaria*
Thiomersal
Potassium chloride
Potassium dihydrogen phosphate
Disodium hydrogen phosphate anhydrous
Sodium chloride
Silicon antifoaming agent
Water for injections

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 10 hours.

6.4. Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Store in the original package.

6.5 Nature and composition of immediate packaging

Polypropylene colourless vial containing 80 ml or 200 ml, with a type I bromobutyl rubber stopper, sealed with an aluminium closure.

Package sizes:

Cardboard box with 1 vial containing 80 ml.

Cardboard box with 1 vial containing 200 ml.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

LABORATORIOS SYVA, S.A.
C/ Marqués de la Ensenada, 16
28004 MADRID
SPAIN

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/18/231/001-012

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation:09/01/2019

10. DATE OF REVISION OF THE TEXT

Detailed information on this veterinary medicinal product is available in the website of the European Medicines Agency <http://www.ema.europa.eu/>.

PROHIBITION OF SALE, SUPPLY AND/OR USE

Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

ANNEX II

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance

LABORATORIOS SYVA, S.A.
Parque Tecnológico de León
C/ Nicostrato Vela M15-M16
24009 León
Spain

Name and address of the manufacturer responsible for batch release

LABORATORIOS SYVA, S.A.
Parque Tecnológico de León
C/ Nicostrato Vela M15-M16
24009 León
Spain

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) the administration of the product to animals will interfere with the implementation of national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

C. STATEMENT OF THE MRLs

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box of 1 vial of 80 ml
Box of 1 vial of 200 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Syvazul BTV suspension for injection for sheep and cattle

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substance(s):

Inactivated bluetongue virus, serotype 1 (BTV-1), strain ALG2006/01 E1	RP* \geq 1
Inactivated bluetongue virus, serotype 4 (BTV-4), strain BTV-4/SPA-1/2004	RP* \geq 1
Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01	RP* \geq 1

* Relative potency measured by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species.

Adjuvants:

Aluminium hydroxide (Al ³⁺)	2.08 mg
Semi-purified saponin from <i>Quillaja saponaria</i>	0.2 mg

Excipient:

Thiomersal	0.1 mg
------------	--------

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

80 ml
200 ml

5. TARGET SPECIES

Sheep and cattle

6. INDICATION(S)**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Sheep: Subcutaneous use.
Cattle: Intramuscular use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s): zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

Once broached use within 10 hours.

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated.

Do not freeze.

Protect from light.

Store in the original package.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

The import, possession, sale, supply and/or use of this veterinary medicinal product may be prohibited in a Member State on the whole or part of its territory, see package leaflet for further information.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

LABORATORIOS SYVA, S.A.
C/ Marqués de la Ensenada, 16
28004 MADRID
SPAIN

16. MARKETING AUTHORISATION NUMBER(S)

17. MANUFACTURER'S BATCH NUMBER
--

Batch {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Vial of 80 ml
Vial of 200 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Syvazul BTV suspension for injection for sheep and cattle

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substance(s):

Inactivated bluetongue virus, serotype 1 (BTV-1), strain ALG2006/01 E1	RP* \geq 1
Inactivated bluetongue virus, serotype 4 (BTV-4), strain BTV-4/SPA-1/2004	RP* \geq 1
Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01	RP* \geq 1

* Relative potency compared to a reference vaccine.

3. PHARMACEUTICAL FORM

Suspension for injection.

4. PACKAGE SIZE

80 ml
200 ml

5. TARGET SPECIES

Sheep and cattle.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Sheep: Subcutaneous use.
Cattle: Intramuscular use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal period(s): zero days.

9. SPECIAL WARNING(S), IF NECESSARY

Shake well before use.

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

Once broached use within 10 hours.

11. SPECIAL STORAGE CONDITIONS

Do not freeze.

Store and transport refrigerated.

Protect from light.

Store in the original package.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

LABORATORIOS SYVA, S.A.

C/ Marqués de la Ensenada, 16

28004 MADRID

SPAIN

16. MARKETING AUTHORISATION NUMBER(S)

EU/2/18/231/001-012

17. MANUFACTURER’S BATCH NUMBER

Batch {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET :

Syvazul BTV suspension for injection for sheep and cattle

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

LABORATORIOS SYVA, S.A.
C/ Marqués de la Ensenada, 16
28004 MADRID
SPAIN

Manufacturer responsible for batch release:

LABORATORIOS SYVA, S.A.
Parque Tecnológico de León
C/ Nicostrato Vela M15-M16
24009 LEÓN
SPAIN

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Syvazul BTV suspension for injection for sheep and cattle

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

Active substances*:

Inactivated bluetongue virus (BTV) RP** \geq 1

* Maximum of two different inactivated bluetongue virus serotypes:

Inactivated bluetongue virus, serotype 1 (BTV-1), strain ALG2006/01 E1
Inactivated bluetongue virus, serotype 4 (BTV-4), strain BTV-4/SPA-1/2004
Inactivated bluetongue virus, serotype 8 (BTV-8), strain BEL2006/01

** Relative potency measured by ELISA in relation to a reference vaccine whose efficacy has been demonstrated by challenge in the target species.

The number and type(s) of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label.

Adjuvants:

Aluminium hydroxide (Al³⁺) 2.08 mg
Semi-purified saponin from *Quillaja saponaria* 0.2 mg

Excipient:

Thiomersal

0.1 mg

Pinkish-white suspension for injection easily homogenised by shaking.

4. INDICATION(S)

Sheep:

For active immunisation of sheep to prevent viraemia* and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/ or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes).

*Below the level of detection by the validated RT-PCR method at $1.32 \log_{10}$ TCID₅₀/ml

Onset of immunity: 39 days after completion of the primary vaccination scheme.

Duration of immunity: one year after completion of the primary vaccination scheme.

Cattle:

For active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1 and/ or 8 and/or to reduce viraemia* caused by bluetongue virus serotype 4 (combination of maximum 2 serotypes).

*Below the level of detection by the validated RT-PCR method at $1.32 \log_{10}$ TCID₅₀/ml

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: one year after completion of the primary vaccination scheme.

5. CONTRAINDICATIONS

None.

6. ADVERSE REACTIONS

The development of local reactions is very common at the site of injection after vaccination.

Erythema associated with mild to moderate oedema is very common from 1 to 6 days after the administration.

A painless nodule that may reach up to 3.8 cm diameter in sheep and 7 cm diameter in cattle develops very commonly after 2 to 6 days and diminishes progressively over time.

An abscess may appear on rare occasions.

Most local reactions disappear or become residual (≤ 1 cm) before 70 days in sheep and 30 days in cattle, although residual nodules can persist after that time.

A transient increase in rectal temperature, not exceeding 2.3 °C, during the 48 hours following vaccination, is very common.

The following might be observed on rare occasions in sheep and on very rare occasions in cattle:

- Reproductive system disorders: abortion, perinatal mortality or premature parturition
- Systemic disorders: apathy, recumbency, fever, anorexia or lethargy.

The following might be observed on very rare occasions in sheep and cattle:

- Reduction in milk production
- Neurological disorders: paralysis, ataxia, blindness or incoordination
- Respiratory tract disorders: pulmonary congestion, dyspnoea
- Digestive tract disorders: rumen atony or bloating
- Hypersensitivity reactions: with hypersalivation
- Death.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Sheep and cattle.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Shake well before use.

Sheep:

Subcutaneous use.

Administer subcutaneously to sheep from 3 months of age, according to the following scheme:

- Primary vaccination: administer a single 2 ml dose
- Revaccination: administer one dose of 2 ml after 12 months.

Cattle:

Intramuscular use.

Administer intramuscularly to cattle from 2 months of age in naïve animals or from 3 months of age in calves born to immune cattle, according to the following scheme:

- Primary vaccination: administer two doses of 4 ml 3 weeks apart
- Revaccination: administer one dose of 4 ml after 12 months.

9. ADVICE ON CORRECT ADMINISTRATION

Shake well before use.

10. WITHDRAWAL PERIOD(S)

Zero days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
Store in the original package.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. The expiry date refers to the last date of that month.

Shelf life after first opening the immediate packaging: 10 hours.

12. SPECIAL WARNING(S)

Special warnings for each target species:

Vaccinate healthy animals only.

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep and cattle.

No information is available on the use of the vaccine in sheep with maternally-derived antibodies.

No information is available on the use of the vaccine containing BTV4 serotype in cattle with maternally-derived antibodies.

Special precautions for use in animals:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

People with known hypersensitivity to aluminium hydroxide, thiomersal or saponins should avoid contact with the veterinary medicinal product.

Pregnancy:

Can be used during pregnancy.

Lactation:

Can be used during lactation.

Fertility:

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or National Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

After administration of a double dose, no other adverse reactions different to those mentioned in 'ADVERSE REACTIONS' were observed.

Incompatibilities:

Do not mix with any other veterinary medicinal product.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

15. OTHER INFORMATION

Pack sizes:

Cardboard box with 1 vial containing 80 ml.

Cardboard box with 1 vial containing 200 ml.

Not all pack sizes may be marketed.

Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

laboratorios syva, s.a.

C/ Marqués de la Ensenada, 16

ES-28004 Madrid

Република България

laboratorios syva, s.a.

C/ Marqués de la Ensenada, 16

ES-28004 Madrid

Lietuva

laboratorios syva, s.a.

C/ Marqués de la Ensenada, 16

ES-28004 Madrid

Luxembourg/Luxemburg

laboratorios syva, s.a.

C/ Marqués de la Ensenada, 16

ES-28004 Madrid

Česká republika

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Danmark

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Deutschland

Virbac Tierarzneimittel GmbH
Rögen 20
DE-23843 Bad Oldesloe
Tel: +494531 805 111

Eesti

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Ελλάδα

CEVA ΕΛΛΑΣ ΕΠΕ
Αγίου Νικολάου 15
EL-17455 – ΑΛΙΜΟΣ
Tel: +302109851200

España

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

France

Exploitant:
Laboratoires Biové
3 rue de Lorraine
62510 Arques

Hrvatska

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Ireland

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Ísland

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Italia

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Κύπρος

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Magyarország

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Malta

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Nederland

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Norge

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Österreich

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Polska

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Portugal

iapsa portuguesa pecuária, lda
Av. Do Atlântico, nº 16 – 11ª piso- Escritório 12
PT-1990-019 Lisboa

România

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Slovenija

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Slovenská republika

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Suomi/Finland

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Sverige

laboratorios syva, s.a.
C/ Marqués de la Ensenada, 16
ES-28004 Madrid

Latvija

laboratorios syva, s.a.

C/ Marqués de la Ensenada, 16

ES-28004 Madrid

United Kingdom (Northern Ireland)

laboratorios syva, s.a.

C/ Marqués de la Ensenada, 16

ES-28004 Madrid